Skip to main content

Table 1 Details of prospective trials included

From: Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

Relevant publication N a Age: Median (range) Phase Systemic Therapy
Bekaii-Saab et al. 2011 [12] 28 56 (26–79) II, Non-randomised Selumetinib
Goldstein et al. 2011 [13] 50 59 (39–78) II, Non-randomised Gemcitabine/Cisplatin
Jensen et al. 2012 [14] 46 66 (37–80) II, Non-randomised Gemcitabine/Oxaliplatin/Panitumumab/Capecitabine
Lassen et al. 2011 [15] 41 61 (35–75) II, Non-randomised Gemcitabine/Oxaliplatin/Capecitabine
Malka et al. 2014 (BINGO) [16] 150 62 (35–75) II, Randomised Gemcitabine/Oxaliplatin ± Cetuximab
Moehler et al. 2014 (AIO) [17] 102 64 (36–84) II, Randomised Gemcitabine ± Sorafenib
Okusaka et al. 2010 (BT22) [18] 83 66 (43–80) II, Randomised Gemcitabine ± Cisplatin
Peck et al. 2012 [19] 9 61 (31–83) II, Non-randomised Lapatinib
Rao et al. 2005 [20] 54 57 (36–76) III, Randomised 5-Fluorouracil/Etoposide/Leucovorin versus Epirubicin/Cisplatin/5-Fluorouracil
Riechelmann et al. 2007 [21] 75 61 (37–84) II, Non-randomised Gemcitabine/Capecitabine
Ferraro et al. 2016 (TACTIC) [22] 48 64 (40–82) II, Non-randomised Gemcitabine/Cisplatin/Panitumumab
Valle et al. 2010 (ABC-02) [2] 410 63 (23–85) III, Randomised Gemcitabine ± Cisplatin
Wagner et al. 2009 [23] 72 62 (36–80) II, Non-randomised Gemcitabine/Oxaliplatin/5-Fluorouracil
  1. aDue to non-availability of some data, 5 patients were not included in overall analysis